Le Lézard
Classified in: Health, Covid-19 virus

COVID-19, ADHD, and Depression: During ADHD Awareness Month in October, CHADD Shines a Spotlight on the Heightened Impact of the Pandemic on Children and Adults with ADHD


LANHAM, Md., Oct. 20, 2020 /PRNewswire-PRWeb/ -- COVID-19, ADHD, and Depression

During ADHD Awareness Month in October, CHADD Shines a Spotlight on the Heightened Impact of the Pandemic on Children and Adults with ADHD

A report published by The Journal of the American Medical Association in September found that symptoms of depression have become three times more prevalent in the United States since the COVID-19 pandemic began. Many individuals have sought out treatment, resulting in a 34 percent increase in anxiety medication and an 18 percent increase in antidepressant medication between mid-February and mid-March 2020.

This staggering statistic is of even greater concern for the 17 million children and adults in the US with attention-deficit/hyperactivity disorder (ADHD), who already have a disproportionately higher risk of experiencing depression than their peers. During ADHD Awareness Month in October, CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder)?the leading nonprofit organization providing support, training, education, and advocacy for the ADHD community?hopes to build greater understanding of the correlation and urges the loved ones of those with ADHD to be especially vigilant during these difficult times.

"ADHD often coexists with other psychological disorders, including depression, anxiety, and substance use issues," said CHADD Professional Expert David W. Goodman, MD, Director of the Adult Attention Deficit Disorder Center of Maryland, and Assistant Professor of the Department of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. "During the best of times, individuals with ADHD can face significant challenges in school, work, and relationships. Now, we layer on the stressors associated with the pandemic?social isolation, job loss, financial problems, home schooling, childcare issues, health concerns, and more?that are causing or exacerbating depression for children and adults in general. Because of increasing organizational demands, these stressors are weighing even more heavily on members of the ADHD community and their ability to manage through it."

ADHD is a neurodevelopmental disorder in children and adults characterized by a persistent pattern of inappropriate levels of attention, impulsivity, and hyperactivity, resulting in daily impairments at school and work, and with family and friends. Nearly 38 percent of adults with ADHD experience depression, compared to eight percent of the general adult population. And approximately 17 percent of children with ADHD experience depression, compared to only three percent of their non-ADHD peers.

While ADHD is one of the most well-researched medical diagnoses in the world, there is still a great deal of inaccurate information circulating, leading to confusion and doubt among uninformed or misinformed audiences. It is important to know that ADHD is highly manageable with an individualized, multimodal treatment approach that can include behavioral interventions, parent and patient training, educational support, and medication.

"Living with ADHD can be challenging in itself, and often goes hand-in-hand with depression," said Robert Cattoi, Chief Executive Officer, CHADD. "COVID-19 has uprooted our lives, and made what was already challenging even more so. We are working from home, educating our children from home, and unable to interact with our friends and family. We want children and adults with ADHD to know they are not alone. CHADD provides numerous resources and support tools to help them. And we want their parents, partners, and friends to be able to recognize the signs of depression?now more than ever?and take action to ensure their loved ones aren't suffering in silence."

The U.S. Centers for Disease Control and Prevention (CDC) defines depression as more than just feeling down or having a bad day, but rather, when a sad mood lasts for an extended period time and interferes with normal, everyday functioning. Symptoms include:

If you or a loved one is experiencing symptoms of depression, please reach out to a mental health professional for help. For the ADHD community, CHADD offers a free ADHD Helpline at 1.866.200.8098, staffed by experienced Health information Specialists Monday through Friday, from 1:00 to 5:00 pm ET. If you or someone you know is experiencing suicidal thoughts, please call the National Suicide Prevention Lifeline at 800.273.8255.

To learn more about ADHD, visit CHADD.org or call 310.306.7070.

About CHADD
CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) is the leading resource on attention-deficit/hyperactivity disorder (ADHD), providing support, training, education, and advocacy for the 17 million children and adults in the United States living with ADHD, their families, educators, and healthcare professionals. As home to the National Resource Center on ADHD, funded by the US Centers for Disease Control and Prevention, CHADD is the most trusted source of reliable, science-based information regarding current medical research and ADHD management. To learn more, visit CHADD.org or call 310.306.7070.

# # #

Contact
Barbara Link
610.668.2855
[email protected]

 

SOURCE CHADD


These press releases may also interest you

at 06:30
Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior...

at 06:28
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Pharma Parenteral Packaging Market ? By Drug Type (Small Molecules, Biologics, Vaccines, Biosimilars, & Others), By Product Type (Bottles, Ampoules,...

at 06:15
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points...

at 06:10
Thermo Fisher Scientific Inc. , the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City. The format will feature presentations by members of Thermo Fisher...

at 06:05
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP...

at 06:05
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's...



News published on and distributed by: